丰倍生物主板IPO过会

Group 1 - The core viewpoint of the article is that Suzhou Fengbei Biotechnology Co., Ltd. has successfully passed the IPO review on the Shanghai Stock Exchange, indicating a positive step towards its public listing [1] - Fengbei Biotechnology is a high-tech enterprise in the field of comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [1] - The company aims to raise approximately 750 million yuan through its IPO, which will be invested in various projects including the production of 300,000 tons of oleic acid methyl ester and 10,000 tons of industrial-grade mixed oil [1] Group 2 - The listing committee has requested Fengbei Biotechnology to explain the reasons and rationality behind the expected decrease or stability in sales and management expenses for 2024, despite anticipated adjustments in customer and product structures and continued revenue growth [1] - The committee also requires the company to address the authenticity of sales revenue and expenses related to industrial-grade mixed oil, considering the main operational data and performance changes for 2024 [1] - Additionally, the committee has asked Fengbei Biotechnology to assess the risks of declining biofuel revenue, the sustainability of industrial-grade mixed oil revenue growth, and the stability of the company's operating performance in light of changes in product structure and competitive advantages [2]